Intelligent Bio-Systems Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Intelligent Bio-Systems Inc.
The system was launched late last year, but a preliminary injunction issued by a federal court in California will now block Qiagen from marketing its GeneReader sequencing system in the US. Illumina had filed a patent claim against the system, and the court found that the claim is likely to succeed.
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
A roundup of recent medtech mergers & acquisitions, strategic alliances, and financings.
Qiagen has acquired privately held Intelligent Bio-Systems, a developer of next-generation sequencing (NGS) instruments aimed at the clinical research market. IBS’ technology, along with a newly expanded collaboration with bioinformatics provider SAP, is the cornerstone of a new NGS initiative at Qiagen.
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Drug Discovery Tools
- Drug Discovery Tools